Literature DB >> 23035587

Inhaled chemotherapy in lung cancer: safety concerns of nanocomplexes delivered.

Paul Zarogoulidis, Chrisostomi Giraleli, Nikos K Karamanos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23035587     DOI： 10.4155/tde.12.77

Source DB:  PubMed          Journal:  Ther Deliv        ISSN： 2041-5990


× No keyword cloud information.
  12 in total

1.  Experimentation with aerosol bonsetan, pirfenidone, treprostinil and sidenafil.

Authors:  Haidong Huang; Paul Zarogoulidis; Sofia Lampaki; John Organtzis; Dimitris Petridis; Konstantinos Porpodis; Antonis Papaiwannou; Vasilis Karageorgiou; Georgia Pitsiou; Ioannis Kioumis; Wolfgang Hohenforst-Schmidt; Qiang Li; Kaid Darwiche; Lutz Freitag; Aggeliki Rapti; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Synthesis and In Vitro Evaluation of Polyethylene Glycol-Paclitaxel Conjugates for Lung Cancer Therapy.

Authors:  Tian Luo; Johannes Magnusson; Véronique Préat; Raphael Frédérick; Cameron Alexander; Cynthia Bosquillon; Rita Vanbever
Journal:  Pharm Res       Date:  2016-03-16       Impact factor: 4.200

Review 3.  Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery.

Authors:  Andrew M Shen; Tamara Minko
Journal:  J Control Release       Date:  2020-07-16       Impact factor: 9.776

Review 4.  Prodrugs and prodrug-activated systems in gene therapy.

Authors:  Semira Sheikh; Daniel Ernst; Armand Keating
Journal:  Mol Ther       Date:  2021-04-06       Impact factor: 11.454

5.  DDMC-p53 gene therapy with or without cisplatin and microwave ablation.

Authors:  Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Joshua Stopek; Thomas Vogl; Frank Hübner; J Francis Turner; Robert Browning; Konstantinos Zarogoulidis; Antonis Drevelegas; Konstantinos Drevelegas; Kaid Darwiche; Lutz Freitag; Harald Rittger
Journal:  Onco Targets Ther       Date:  2015-05-20       Impact factor: 4.147

6.  Learning from the Cardiologists and Developing Eluting Stents Targeting the Mtor Pathway for Pulmonary Application; A Future Concept for Tracheal Stenosis.

Authors:  Paul Zarogoulidis; Kaid Darwiche; Kosmas Tsakiridis; Helmut Teschler; Lonny Yarmus; Konstantinos Zarogoulidis; Lutz Freitag
Journal:  J Mol Genet Med       Date:  2013-08-26

7.  Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol.

Authors:  Paul Zarogoulidis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Dionysios Spyratos; Georgia Pitsiou; Dimitris Petridis; Athanasia Pataka; Haidong Huang; Qiang Li; Lonny Yarmus; Wolfgang Hohenforst-Schmidt; Nikolaos Pezirkianidis; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2014-08-12       Impact factor: 4.162

8.  Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.

Authors:  Georgia Pitsiou; Paul Zarogoulidis; Dimitris Petridis; Ioannis Kioumis; Sofia Lampaki; John Organtzis; Konstantinos Porpodis; Antonis Papaiwannou; Theodora Tsiouda; Wolfgang Hohenforst-Schmidt; Stylianos Kakolyris; Konstantinos Syrigos; Haidong Huang; Qiang Li; J Francis Turner; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2014-10-07       Impact factor: 4.162

Review 9.  Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature.

Authors:  Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Georgia Pitsiou; Bernd Linsmeier; Drosos Tsavlis; Ioannis Kioumis; Eleni Papadaki; Lutz Freitag; Theodora Tsiouda; J Francis Turner; Robert Browning; Michael Simoff; Nikolaos Sachpekidis; Kosmas Tsakiridis; Bojan Zaric; Lonny Yarmus; Sofia Baka; Grigoris Stratakos; Harald Rittger
Journal:  J Cancer       Date:  2016-01-13       Impact factor: 4.207

10.  Preparation and toxicological assessment of functionalized carbon nanotube-polymer hybrids.

Authors:  Nikos D Koromilas; Georgia Ch Lainioti; Chrisostomi Gialeli; Despoina Barbouri; Katerina B Kouravelou; Nikos K Karamanos; George A Voyiatzis; Joannis K Kallitsis
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.